» Articles » PMID: 12523669

The Activation Energy at Tg and the Fragility Index of Indomethacin, Predicted from the Influence of the Heating Rate on the Temperature Position and on the Intensity of Thermally Stimulated Depolarization Current Peak

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2003 Jan 14
PMID 12523669
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The purpose of this study was to estimate the activation energy at the glass transition temperature (and the fragility index) of amorphous indomethacin from the influence of heating rate on the features of the relaxation peaks obtained by thermally stimulated depolarization currents (TSDC) and to compare the obtained results with those obtained by other procedures based on TSDC data.

Methods: The glass transition temperature region of amorphous indomethacin was characterized at different heating rates by TSDC in a way similar to that used to determine the kinetics of the glass transition relaxation by differential scanning calorimetry. The features of a thermal sampled TSDC peak, namely the temperature location and the intensity, depend on the heating rate.

Results: The activation energy for structural relaxation (directly related to glass fragility) was estimated from the heating rate dependence of the TSDC peak location, T(m), and of the maximum intensity of the TSDC peak, I(T(m)).

Conclusions: The methods for determining the activation energy for structural relaxation and fragility of indomethacin from TSDC data obtained with different heating rates were compared with other procedures previously proposed. TSDC, which is not a very familiar technique in the community of pharmaceutical scientists, proved to be a very convenient technique to study molecular mobility and to determine the fragility index in glass-forming systems. The value of approximately 60 appears as a reasonable value of the fragility index of indomethacin.

Citing Articles

Evaluation of Different Thermoanalytical Methods for the Analysis of the Stability of Naproxen-Loaded Amorphous Solid Dispersions.

Szabo E, Haraszti A, Zahonyi P, Vadas D, Csontos I, Nagy Z Pharmaceutics. 2022; 14(11).

PMID: 36432698 PMC: 9692747. DOI: 10.3390/pharmaceutics14112508.


Thermal Stability of Amorphous Solid Dispersions.

Jelic D Molecules. 2021; 26(1).

PMID: 33466393 PMC: 7795217. DOI: 10.3390/molecules26010238.


Fragility and basic process energies in vitrifying systems.

Martinez-Garcia J, Rzoska S, Drozd-Rzoska A, Starzonek S, Mauro J Sci Rep. 2015; 5:8314.

PMID: 25660971 PMC: 4321169. DOI: 10.1038/srep08314.


Enhancement of the physical stability of amorphous indomethacin by mixing it with octaacetylmaltose. inter and intra molecular studies.

Kaminska E, Adrjanowicz K, Zakowiecki D, Milanowski B, Tarnacka M, Hawelek L Pharm Res. 2014; 31(10):2887-903.

PMID: 24831310 DOI: 10.1007/s11095-014-1385-4.


Acoustic-like dynamics of amorphous drugs in the THz regime.

Pogna E, Rodriguez-Tinoco C, Krisch M, Rodriguez-Viejo J, Scopigno T Sci Rep. 2013; 3:2518.

PMID: 23989304 PMC: 3757359. DOI: 10.1038/srep02518.

References
1.
He R, Craig D . An investigation into the thermal behaviour of an amorphous drug using low frequency dielectric spectroscopy and modulated temperature differential scanning calorimetry. J Pharm Pharmacol. 2001; 53(1):41-8. DOI: 10.1211/0022357011775172. View

2.
Correia N, Ramos J, Descamps M, Collins G . Molecular mobility and fragility in indomethacin: a thermally stimulated depolarization current study. Pharm Res. 2002; 18(12):1767-74. DOI: 10.1023/a:1013339017070. View

3.
Andronis V, Zografi G . The molecular mobility of supercooled amorphous indomethacin as a function of temperature and relative humidity. Pharm Res. 1998; 15(6):835-42. DOI: 10.1023/a:1011960112116. View

4.
Hancock B, Zografi G . Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997; 86(1):1-12. DOI: 10.1021/js9601896. View

5.
Shamblin S, Hancock B, Dupuis Y, Pikal M . Interpretation of relaxation time constants for amorphous pharmaceutical systems. J Pharm Sci. 2000; 89(3):417-27. DOI: 10.1002/(SICI)1520-6017(200003)89:3<417::AID-JPS12>3.0.CO;2-V. View